| Abstract [eng] |
The aim of this study was to evaluate the sensitization with HLA antigens in kidney transplant recipients, who received induction therapy with monoclonal antibodies against IL-2R and in the group of patients, who were only under the triple drug therapy. This study comprises recipients, who received kidney transplant in the year 2000-2005, and who were tested for panel reactive antibody test before and after transplantation (Tx). The total number of 189 kidney transplant recipients takes part in this study. 83 received monoclonal antibodies against IL-2R (basiliximab or daclizumab), others (n=106) – did not. These groups were unequal in comparison to the main factors causing sensitization with HLA antigens. The group of patients, who received induction therapy with monoclonal antibodies had more blood transfuzions (72% vs. 57,3%), and previous transplantations (9,6% vs. 7,5%), in comparison with the other group. Only the number of pregnancies was higher in the group of patients who were only under the triple drug therapy (47,7% vs. 30,8%). Statistical analyses were caried out using chi-square test, differences were considered significant at p<0,05. 58% (110/189) of kidney transplant recipients were unsensitized (PRA 0-10%) before Tx, the rest 42% (79/189) were sensitized, from which 14% (11/189) were highly sensitized (PRA 50-100%). After Tx the number of medium sensitized (PRA 11-50%) kidney transplant recipients, who received induction therapy by monoclonal antibodies, increased by 2%. The group of patients, who were only under the triple drug therapy, increased the number of highly sensitized patients by 7%. Comparing the results of these groups after Tx, clears out, that both groups increased the number of sensitized patients after Tx, only the increase in the group, which was only under the triple drug therapy was greater, because this group increased the number of highly sensitized, while the other group did not increase the number of highly sensitized patients. But, the differences between the groups were not statistically significant. The rezults showed that induction therapy with monoclonal antibodies was not very effective in preventing the rate of sensitization in posttransplant period, it could be due to the higher number of sensitizing factors in the group, or indicate us that induction therapy is not sufficient enough to prevent senitization after kidney transplantation. |
